Cancer

Multiple Sclerosis Drug Could Reduce Painful Side Effects of Common Cancer Treatment

Researchers from Saint Louis University School of Medicine have discovered why many multiple myeloma patients experience severe pain when treated with the anticancer drug bortezomib. The study, which was published on April 27 in the Journal of Experimental Medicine, suggests that a drug already approved to treat multiple sclerosis could mitigate this effect and allow myeloma

In Laboratory, SLU Scientist Turns Off Chemo Pain

In a recent paper published in the journal Pain, Saint Louis University researchers describe their success in an animal model in turning off the excruciating pain that often accompanies a colorectal cancer drug. Daniela Salvemini, Ph.D., professor of pharmacology and physiology at SLU, studies pain pathways, the series of interactions between molecular-level components that lead to

Higher doses of radiation don’t improve survival in prostate cancer

A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. The analysis, which included 104 radiation therapy oncology groups across North America, was led by researchers at Washington University School of Medicine in St. Louis. Past studies have shown that

March 22nd, 2018|Categories: Around The State, Cancer|Tags: , , , |

SLU Researchers Discover Structure of Protein Associated with Inflammation, Parkinson’s

In a recent paper published in Nature Communications, Saint Louis University scientists report that they have determined the structure of a key protein that is involved in the body’s inflammatory response. This finding opens the door to developing new treatments for a wide range of illnesses, from heart disease, diabetes and cancer to neurodegenerative disorders, including

CRISPR enhances cancer immunotherapy

Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient’s own immune cells — called T cells — and supercharging them to home in on and attack specific blood cancers, such as hard-to-treat acute lymphoblastic leukemia and non-Hodgkin lymphoma. But so far, these T

Similarities found in cancer initiation in kidney, liver, stomach, pancreas

Recent research at Washington University School of Medicine in St. Louis demonstrated that mature cells in the stomach sometimes revert back to behaving like rapidly dividing stem cells. Now, the researchers have found that this process may be universal; no matter the organ, when tissue responds to certain types of injury, mature cells seem to

February 22nd, 2018|Categories: Around The State, Cancer|Tags: , , , |

Cutting off cervical cancer’s fuel supply stymies tumors

Cancer therapies have improved — in some cases dramatically — over the past two decades, but treatment for cervical cancer has remained largely unchanged. All patients receive radiation and chemotherapy, yet despite the aggressive approach, the regimen fails in about one-third of patients with cervical cancer that has spread beyond the cervix but not outside

February 15th, 2018|Categories: Around The State, Cancer, Disease Specific|Tags: , , , |

Light-triggered nanoparticles show promise against metastatic cancer

A new anti-cancer strategy wields light as a precision weapon. Unlike traditional light therapy — which is limited to the skin and areas accessible with an endoscope — this technique can target and attack cancer cells that have spread deep inside the body, according to researchers at Washington University School of Medicine in St. Louis.

January 26th, 2018|Categories: Around The State, Cancer, Disease Specific|Tags: , , |